Advertisement

Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)

  • C. S. Pitchumoni
  • C. S. Pitchumoni
  • C. S. Pitchumoni
Chapter

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disorder in adults worldwide. NAFLD and nonalcoholic steatohepatitis (NASH) represent the hepatic manifestation of “metabolic syndrome.” NAFLD-related cirrhosis is becoming the most common cause of cirrhosis, a cause of primary hepatocellular carcinoma, and rarely intra-hepatic cholangiocarcinoma. The prevalence of NAFLD after age 75 tends to decrease perhaps due to early mortality from comorbid effects of the metabolic syndrome. Most people with NAFLD are asymptomatic. The majority of patients come to the clinician’s attention usually because of abnormal serum aspartate aminotransferase or alanine aminotransferase. A minority of patients progress to NASH, cirrhosis, and even hepatoma. The diagnosis of NAFLD is made clinically, but NASH is a histological term. Presence of inflammatory cells, ballooning degeneration of hepatocytes, Mallory bodies and perivenular collagen deposition. The treatment is with lifestyle modification, weight reduction, and pharmacological agents. In addition to lipid-lowering agents, metformin, vitamins E and C and rosiglitazone, ursodeoxycholic acid, and pentoxifylline are suggested therapies.

Keywords

Metabolic Syndrome Bariatric Surgery Liver Biopsy Fatty Liver Liver Fibrosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis. 1986;8:283–98.PubMedGoogle Scholar
  2. 2.
    Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–31.PubMedGoogle Scholar
  3. 3.
    Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology. 2003;37:1202–19.PubMedGoogle Scholar
  4. 4.
    Floreani A. Liver diseases in the elderly: an update. Dig Dis. 2007;25:138–43.PubMedGoogle Scholar
  5. 5.
    Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–8.PubMedGoogle Scholar
  6. 6.
    Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol. 2011;26 Suppl 1:163–72.PubMedGoogle Scholar
  7. 7.
    Mohan V, Farooq S, Deepa M, Ravikumar R, Pitchumoni CS. Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Res Clin Pract. 2009;84:84–91.PubMedGoogle Scholar
  8. 8.
    Ong J, Younossi ZM, Reddy V, et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl. 2001;7:797–801.PubMedGoogle Scholar
  9. 9.
    Cuadrado A, Orive A, Garcia-Suarez C, et al. Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma. Obes Surg. 2005;15:442–6.PubMedGoogle Scholar
  10. 10.
    Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134–40.PubMedGoogle Scholar
  11. 11.
    Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123:1705–25.PubMedGoogle Scholar
  12. 12.
    de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008;48 Suppl 1:S104–12.PubMedGoogle Scholar
  13. 13.
    Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med. 2008;75:721–8.PubMedGoogle Scholar
  14. 14.
    Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960–1994. Int J Obes Relat Metab Disord. 1998;22:39–47.PubMedGoogle Scholar
  15. 15.
    Prentice AM. The emerging epidemic of obesity in developing countries. Int J Epidemiol. 2006;35:93–9.PubMedGoogle Scholar
  16. 16.
    Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. Gastroenterology. 2007;132:2087–102.PubMedGoogle Scholar
  17. 17.
    Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303:235–41.PubMedGoogle Scholar
  18. 18.
    Ledikwe JH, Smiciklas-Wright H, Mitchell DC, et al. Nutritional risk assessment and obesity in rural older adults: a sex difference. Am J Clin Nutr. 2003;77:551–8.PubMedGoogle Scholar
  19. 19.
    Villareal DT, Apovian CM, Kushner RF, Klein S. Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society. Am J Clin Nutr. 2005;82:923–34.PubMedGoogle Scholar
  20. 20.
    Angulo P. Obesity and nonalcoholic fatty liver disease. Nutr Rev. 2007;65:S57–63.PubMedGoogle Scholar
  21. 21.
    Kowdley KV, Caldwell S. Nonalcoholic steatohepatitis: a twenty-first century epidemic? J Clin Gastroenterol. 2006;40 Suppl 1:S2–4.PubMedGoogle Scholar
  22. 22.
    Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–95.PubMedGoogle Scholar
  23. 23.
    Chitturi S, Farrell GC, George J. Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock? J Gastroenterol Hepatol. 2004;19:368–74.PubMedGoogle Scholar
  24. 24.
    Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006;40 Suppl 1:S5–10.PubMedGoogle Scholar
  25. 25.
    Floreani A. Liver disorders in the elderly. Best Pract Res Clin Gastroenterol. 2009;23:909–17.PubMedGoogle Scholar
  26. 26.
    Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132:112–7.PubMedGoogle Scholar
  27. 27.
    Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis. 2009;13:511–31.PubMedGoogle Scholar
  28. 28.
    Tabibian JH, Lazo M, Durazo FA, et al. Nonalcoholic fatty liver disease across ethno-racial groups: do Asian-American adults represent a new at-risk population? J Gastroenterol Hepatol. 2011;26:501–9.PubMedGoogle Scholar
  29. 29.
    Duseja A. Nonalcoholic fatty liver disease in India—a lot done, yet more required! Indian J Gastroenterol. 2010;29:217–25.PubMedGoogle Scholar
  30. 30.
    Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990;12:1106–10.PubMedGoogle Scholar
  31. 31.
    Silverman JF, O’Brien KF, Long S, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol. 1990;85:1349–55.PubMedGoogle Scholar
  32. 32.
    Mouralidarane A, Lin C, Suleyman N, Soeda J, Oben J. Practical management of the increasing burden of non-alcoholic fatty liver disease. Frontline Gastroenterol. 2010;1(3):149–55.Google Scholar
  33. 33.
    Speliotes EK, Massaro JM, Hoffmann U, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology. 2010;51:1979–87.PubMedGoogle Scholar
  34. 34.
    Kral JG, Schaffner F, Pierson Jr RN, Wang J. Body fat topography as an independent predictor of fatty liver. Metabolism. 1993;42:548–51.PubMedGoogle Scholar
  35. 35.
    Eguchi Y, Eguchi T, Mizuta T, et al. Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease. J Gastroenterol. 2006;41:462–9.PubMedGoogle Scholar
  36. 36.
    Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121:91–100.PubMedGoogle Scholar
  37. 37.
    Falchuk KR, Fiske SC, Haggitt RC, et al. Pericentral hepatic fibrosis and intracellular hyalin in diabetes mellitus. Gastroenterology. 1980;78:535–41.PubMedGoogle Scholar
  38. 38.
    Harrison SA, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Liver Dis. 2004;8:861–79, ix.Google Scholar
  39. 39.
    Pantsari MW, Harrison SA. Nonalcoholic fatty liver disease presenting with an isolated elevated alkaline phosphatase. J Clin Gastroenterol. 2006;40:633–5.PubMedGoogle Scholar
  40. 40.
    Vuppalanchi R, Gould RJ, Wilson LA, et al. Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network. Hepatol Int. 2011;6:379–85.Google Scholar
  41. 41.
    Anstee QM, McPherson S, Day CP. How big a problem is non-alcoholic fatty liver disease? BMJ. 2011;343:d3897.PubMedGoogle Scholar
  42. 42.
    McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8:521–33, viii.Google Scholar
  43. 43.
    Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001;21:3–16.PubMedGoogle Scholar
  44. 44.
    Mottin CC, Moretto M, Padoin AV, et al. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg. 2004;14:635–7.PubMedGoogle Scholar
  45. 45.
    Park SH, Kim PN, Kim KW, et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology. 2006;239:105–12.PubMedGoogle Scholar
  46. 46.
    Lee SW, Park SH, Kim KW, et al. Unenhanced CT for assessment of macrovesicular hepatic steatosis in living liver donors: comparison of visual grading with liver attenuation index. Radiology. 2007;244:479–85.PubMedGoogle Scholar
  47. 47.
    Angulo P. Noninvasive assessment of fibrosis and steatosis in NASH and ASH. Gastroenterol Clin Biol. 2009;33:940–8.PubMedGoogle Scholar
  48. 48.
    McPherson S, Stewart SF, Henderson E, et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59:1265–9.PubMedGoogle Scholar
  49. 49.
    Yoneda M, Fujita K, Inamori M, Tamano M, Hiriishi H, Nakajima A. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut. 2007;56:1330–1.PubMedGoogle Scholar
  50. 50.
    Yin M, Talwalkar JA, Glaser KJ, et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol. 2007;5:1207–13e2.Google Scholar
  51. 51.
    Koek GH, Liedorp PR, Bast A. The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta. 2011;412:1297–305.PubMedGoogle Scholar
  52. 52.
    Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114:842–5.PubMedGoogle Scholar
  53. 53.
    Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr. 1999;18:353–8.PubMedGoogle Scholar
  54. 54.
    DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–94.PubMedGoogle Scholar
  55. 55.
    Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35:373–9.PubMedGoogle Scholar
  56. 56.
    Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844–50.PubMedGoogle Scholar
  57. 57.
    Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450–5.PubMedGoogle Scholar
  58. 58.
    Pagano G, Pacini G, Musso G, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology. 2002;35:367–72.PubMedGoogle Scholar
  59. 59.
    Nelson JE, Wilson L, Brunt EM, et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology. 2011;53:448–57.PubMedGoogle Scholar
  60. 60.
    Moirand R, Mortaji AM, Loreal O, Paillard F, Brissot P, Deugnier Y. A new syndrome of liver iron overload with normal transferrin saturation. Lancet. 1997;349:95–7.PubMedGoogle Scholar
  61. 61.
    Mendler MH, Turlin B, Moirand R, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology. 1999;117:1155–63.PubMedGoogle Scholar
  62. 62.
    George DK, Goldwurm S, MacDonald GA, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology. 1998;114:311–8.PubMedGoogle Scholar
  63. 63.
    Medina J, Fernandez-Salazar LI, Garcia-Buey L, Moreno-Otero R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care. 2004;27:2057–66.PubMedGoogle Scholar
  64. 64.
    Shepherd PR, Kahn BB. Glucose transporters and insulin action—implications for insulin resistance and diabetes mellitus. N Engl J Med. 1999;341:248–57.PubMedGoogle Scholar
  65. 65.
    Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001;294:2166–70.PubMedGoogle Scholar
  66. 66.
    Barsh GS, Farooqi IS, O’Rahilly S. Genetics of body-weight regulation. Nature. 2000;404:644–51.PubMedGoogle Scholar
  67. 67.
    Chitturi S, Farrell G, Frost L, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology. 2002;36:403–9.PubMedGoogle Scholar
  68. 68.
    Bouloumie A, Marumo T, Lafontan M, Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J. 1999;13:1231–8.PubMedGoogle Scholar
  69. 69.
    Loffreda S, Yang SQ, Lin HZ, et al. Leptin regulates proinflammatory immune responses. FASEB J. 1998;12:57–65.PubMedGoogle Scholar
  70. 70.
    Ikejima K, Honda H, Yoshikawa M, et al. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology. 2001;34:288–97.PubMedGoogle Scholar
  71. 71.
    Garg R, Tripathy D, Dandona P. Insulin resistance as a proinflammatory state: mechanisms, mediators, and therapeutic interventions. Curr Drug Targets. 2003;4:487–92.PubMedGoogle Scholar
  72. 72.
    Chaldakov GN, Stankulov IS, Hristova M, Ghenev PI. Adipobiology of disease: adipokines and adipokine-targeted pharmacology. Curr Pharm Des. 2003;9:1023–31.PubMedGoogle Scholar
  73. 73.
    Stefan N, Stumvoll M. Adiponectin—its role in metabolism and beyond. Horm Metab Res. 2002;34:469–74.PubMedGoogle Scholar
  74. 74.
    Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87–91.PubMedGoogle Scholar
  75. 75.
    Bruun JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab. 2003;285:E527–33.PubMedGoogle Scholar
  76. 76.
    Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:691–701.PubMedGoogle Scholar
  77. 77.
    Merrell MD, Cherrington NJ. Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metab Rev. 2011;43:317–34.PubMedGoogle Scholar
  78. 78.
    Tiniakos DG. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems. Eur J Gastroenterol Hepatol. 2010;22:643–50.PubMedGoogle Scholar
  79. 79.
    Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.PubMedGoogle Scholar
  80. 80.
    Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356–62.PubMedGoogle Scholar
  81. 81.
    Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:195–203.PubMedGoogle Scholar
  82. 82.
    Richardson MM, Jonsson JR, Powell EE, et al. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology. 2007;133:80–90.PubMedGoogle Scholar
  83. 83.
    Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.PubMedGoogle Scholar
  84. 84.
    Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–112.PubMedGoogle Scholar
  85. 85.
    Regimbeau JM, Colombat M, Mognol P, et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl. 2004;10:S69–73.PubMedGoogle Scholar
  86. 86.
    Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–85.PubMedGoogle Scholar
  87. 87.
    Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med. 1997;126:137–45.PubMedGoogle Scholar
  88. 88.
    Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–73.PubMedGoogle Scholar
  89. 89.
    Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372–84.PubMedGoogle Scholar
  90. 90.
    Anstee QM, Daly AK, Day CP. Genetics of alcoholic and nonalcoholic fatty liver disease. Semin Liver Dis. 2011;31:128–46.PubMedGoogle Scholar
  91. 91.
    Clark JM. Weight loss as a treatment for nonalcoholic fatty liver disease. J Clin Gastroenterol. 2006;40 Suppl 1:S39–43.PubMedGoogle Scholar
  92. 92.
    Perlemuter G, Bigorgne A, Cassard-Doulcier AM, Naveau S. Nonalcoholic fatty liver disease: from pathogenesis to patient care. Nat Clin Pract Endocrinol Metab. 2007;3:458–69.PubMedGoogle Scholar
  93. 93.
    Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol. 2012;56(1):255–66.PubMedGoogle Scholar
  94. 94.
    Tsochatzis EA, Papatheodoridis GV. Is there any progress in the treatment of non-alcoholic fatty liver disease? World J Gastrointest Pharmacol Ther. 2011;2:1–5.PubMedGoogle Scholar
  95. 95.
    Expert panel on the identification, evaluation, and treatment of overweight and obesity in adults. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998;158:1855–67.Google Scholar
  96. 96.
    Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol. 1991;12:224–9.PubMedGoogle Scholar
  97. 97.
    Valori R. Non-alcoholic fatty liver disease: a non-problem or a public health catastrophe? Frontline Gastroenterol. 2010;1:147–8.Google Scholar
  98. 98.
    Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology. 2005;41:690–5.PubMedGoogle Scholar
  99. 99.
    Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010;376:1916–22.PubMedGoogle Scholar
  100. 100.
    Ratziu V, Pienar L. Pharmacological therapy for non-alcoholic steatohepatitis: how efficient are thiazolidinediones? Hepatol Res. 2011;41:687–95.PubMedGoogle Scholar
  101. 101.
    Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet. 2001;358:893–4.PubMedGoogle Scholar
  102. 102.
    Nair S, Diehl AM, Wiseman M, et al. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther. 2004;20:23–8.PubMedGoogle Scholar
  103. 103.
    Ratziu V, Charlotte F. A one-year randomized, placebo-controlled, double-blind trial of rosiglitazone in non alcoholic steatohepatitis. Result of the FLIRT pilot trial. J Hepatol. 2006;44:201A.Google Scholar
  104. 104.
    Harrison SA, Torgerson S, Hayashi P, et al. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003;98:2485–90.PubMedGoogle Scholar
  105. 105.
    Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–85.PubMedGoogle Scholar
  106. 106.
    Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004;39:770–8.PubMedGoogle Scholar
  107. 107.
    Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad Med J. 2006;82:315–22.PubMedGoogle Scholar
  108. 108.
    Van Wagner LB, Koppe SW, Brunt EM, et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol. 2011;10:277–86.PubMedGoogle Scholar
  109. 109.
    Shaffer EA. Bariatric surgery: a promising solution for nonalcoholic steatohepatitis in the very obese. J Clin Gastroenterol. 2006;40 Suppl 1:S44–50.PubMedGoogle Scholar
  110. 110.
    Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–37.PubMedGoogle Scholar
  111. 111.
    Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008;6:1396–402.PubMedGoogle Scholar
  112. 112.
    Flum DR, Salem L, Elrod JA, et al. Early mortality among Medicare beneficiaries undergoing bariatric surgical procedures. JAMA. 2005;294:1903–8.PubMedGoogle Scholar
  113. 113.
    Abu-Abeid S, Keidar A, Szold A. Resolution of chronic medical conditions after laparoscopic adjustable silicone gastric banding for the treatment of morbid obesity in the elderly. Surg Endosc. 2001;15:132–4.PubMedGoogle Scholar
  114. 114.
    McGovern BH. Hepatic steatosis in HIV/HCV-coinfected patients: time to reevaluate! Gastroenterology. 2011;140:772–5.PubMedGoogle Scholar
  115. 115.
    National Cholesterol Education Program (NCEP). Third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421.Google Scholar
  116. 116.
    Ferrell GC, van Rooven D, Gan L et al. NASH is an inflammatory disorder: pathogenetic, prognostic and therapeutic implications. Gut Liver. 2012;6:149–71.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • C. S. Pitchumoni
    • 1
  • C. S. Pitchumoni
    • 2
  • C. S. Pitchumoni
    • 3
  1. 1.Robert Wood Johnson School of Medicine, Drexel University School of MedicinePhiladelphiaUSA
  2. 2.New York Medical CollegeVallhalaUSA
  3. 3.Gastroenterology, Hepatology and NutritionSaint Peter’s University HospitalNew BrunswickUSA

Personalised recommendations